Taiwan Journal of Ophthalmology

REVIEW ARTICLE
Year
: 2020  |  Volume : 10  |  Issue : 3  |  Page : 174--180

Progress in the pathogenesis of thyroid-associated ophthalmopathy and new drug development


Yazhuo Huang, Sijie Fang, Shuo Zhang, Huifang Zhou 
 Department of Ophthalmology, Shanghai Ninth People's Hospital, Shanghai JiaoTong University School of Medicine; Shanghai Key Laboratory of Orbital Diseases and Ocular Oncology, Shanghai, China

Correspondence Address:
Dr. Huifang Zhou
Department of Ophthalmology, Shanghai Ninth People's Hospital, Shanghai JiaoTong University School of Medicine, 639 Zhizaoju Road, Huangpu, Shanghai
China

Thyroid-associated ophthalmopathy (TAO) is the most common extrathyroidal manifestation of toxic diffuse goiter (Graves' disease), also known as Graves' ophthalmopathy/orbitopathy. As an organ-specific autoimmune disease, the pathogenesis of TAO is still unclear. In recent years, great progress has been made in revealing the mechanism of TAO. Various biological and immunosuppressive agents have emerged in an endless stream, showing encouraging results. Strengthening the basic research, establishing ideal animal models, deeply understanding the pathogenesis, and developing novel targeted drugs are of great significance to guide the clinical diagnosis and management of TAO and improve the prognosis of patients.


How to cite this article:
Huang Y, Fang S, Zhang S, Zhou H. Progress in the pathogenesis of thyroid-associated ophthalmopathy and new drug development.Taiwan J Ophthalmol 2020;10:174-180


How to cite this URL:
Huang Y, Fang S, Zhang S, Zhou H. Progress in the pathogenesis of thyroid-associated ophthalmopathy and new drug development. Taiwan J Ophthalmol [serial online] 2020 [cited 2020 Oct 28 ];10:174-180
Available from: https://www.e-tjo.org/article.asp?issn=2211-5056;year=2020;volume=10;issue=3;spage=174;epage=180;aulast=Huang;type=0